Multi-cancer blood tests found far more cancers in 2026’s biggest trials, but we don’t yet know if they save lives. Here’s what the research shows, in plain English.
Why this matters
When cancer is found early, survival can be dramatically better. In one published study, bladder cancer had about a 96% five-year survival rate when caught early, compared with about 6% once it had spread.
The problem is that we only have routine screening for a few cancers: breast, colorectal, cervical, lung (for higher-risk people) and, optionally, prostate. Many of the deadliest cancers, like pancreatic, ovarian, liver and stomach, have no screening test at all. They’re usually found after symptoms appear, often too late.
Multi-cancer early detection tests, or MCED tests, aim to change that with a single annual blood draw.
How the tests work
As cells die, they release fragments of DNA into your blood, called cell-free DNA. Tumors do too. The leading test, Galleri from GRAIL, reads chemical tags on that DNA called methylation patterns. Cancer cells have distinctive patterns, and an AI model trained on thousands of samples looks for them.
The test answers two questions: is there a cancer signal, and if so, where in the body is it likely coming from?
A positive result is not a diagnosis. It means a cancer signal was detected. Confirming cancer takes follow-up scans and often a biopsy.
What the big studies found
Two large studies of Galleri reported full results in 2026.
PATHFINDER 2 (North America)
- 35,878 adults aged 50+ at 30+ health systems, all tested
- Found more than 7 times as many cancers as usual screening alone
- About 62% of positive results were confirmed cancer
- Only 0.6% needed an invasive procedure, and about 90% of those weren’t surgery
- Published in Nature Medicine, September 2026
NHS-Galleri (England)
- About 142,000 adults aged 50–77, randomly split: half tested, half not
- Found about 4 times as many cancers through screening (1,173 vs 290)
- Missed its main goal of fewer stage III and IV cancers combined
- 14% fewer stage IV cancers (342 vs 397), growing to 26% fewer by year 3
- Under 1% had trial-related side effects, none serious
- Published in the New England Journal of Medicine, September 2026
The NHS-Galleri result is the one to understand. The test didn’t reduce the combined number of stage III and IV cancers. But it did cut stage IV diagnoses, likely by shifting some cancers from stage IV to stage III, which often means better odds. The journal paper reports that stage IV reduction as borderline, not formally significant.
What no study has shown yet is that these tests help people live longer. That takes years more follow-up.
Where things stand now
The FDA. Galleri has been sold as a lab-developed test but isn’t FDA approved. On September 23, 2026, an FDA advisory panel voted 7–2, with one abstention, that its benefits outweigh its risks for adults 50 and older. That’s the first time an FDA panel has reviewed a multi-cancer test for approval. The FDA’s final decision is still pending.
Other tests. Exact Sciences’ Cancerguard, launched in 2025 for adults 50–84, combines tumor DNA with blood proteins. In development studies it caught about 68% of six of the deadliest cancers. It also isn’t FDA approved, and its numbers come from smaller case-control studies, not screening trials.
Cost. Galleri lists at $949 and Cancerguard at $689. Insurance generally doesn’t cover them, and follow-up scans after a positive result cost extra.
The concerns
- False alarms. Roughly 4 in 10 positive results aren’t cancer, which can mean scans, biopsies and anxiety.
- Missed cancers. The tests are better at finding advanced cancers than small early ones, and a negative result can give false reassurance.
- Overdiagnosis. Some cancers found would never have caused harm, and treating them has real side effects.
- Strain on the system. A 2026 JAMA study linked the NHS trial’s first year to longer diagnostic waits for some suspected cancers in participating regions, though it didn’t prove cause.
- Fairness. At current prices, access depends on who can pay.
What to do with this
These tests add to standard screening; they don’t replace it. Keep up with your mammograms, colon screening, cervical screening and, if eligible, lung scans.
If you’re curious about a multi-cancer test, ask your doctor:
- Given my age, history and risk, would this add anything for me?
- If it’s positive, what scans would follow, and would insurance cover them?
- What happens if the scans find nothing?
Experts agree on one point: only take the test if you’re ready to follow through on a positive result.
Want the full story? Episode 1 of our podcast walks through every study in detail. Next up: cancer prevention and the surprising research on GLP-1 medications.
This post is for education, not medical advice.
Brought to you by Larson Nutrition, personalized metabolic health coaching that starts with a free health assessment, and Larson Botanicals, small-batch organic skincare and soy-coconut candles made for sensitive skin.